Stevanato Group S.p.a. · NYSE:STVN
Stevanato — Q2 2022 Earnings Presentation
26 slides from Stevanato's earnings presentation, Aug 4, 2022
Slide 1: Second Quarter 2022 Financial Results
Second Quarter 2022 Financial Results August 4, 2022 Exhibit 99.1
Slide 2: Safe-Harbor Statement
Safe-Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. (“we”, “our”, “us”, “Stevanato Group” or the “Company”).
Slide 3: Earnings Call Speakers
Franco Stevanato Executive Board Chairman Stevanato Group First Quarter 2022 Earnings Call Speakers Second Quarter 2022 Financial Results Franco Moro CEO Marco Dal Lago CFO Lisa Miles SVP IR
Slide 4: Franco Stevanato, Executive Chairman
Franco Stevanato Executive Chairman
Slide 5: Executing on long-term strategic plan to drive sustainable organic growth
Executing on long-term strategic plan to drive sustainable organic growth increase our mix of high value solutions expand EBITDA margins Creating a track record of performance Operating in an environment of robust demand, with attractive end markets characterized by durable, secular multi-year drive
Slide 6: Strong Second Quarter in a Challenging Environment
Strong Second Quarter in a Challenging Environment Delivered double-digit revenue growth, expanded gross profit margin and increased contributions from high value solutions that reached record levels; Raising fiscal year 2022 guidance Second Quarter 2022 Financial Results *Adjusted DEPS, adjusted EB
Slide 7: Advancing Progress on FY 2022 Industrial Plan
Advancing Progress on FY 2022 Industrial Plan Second Quarter 2022 Financial Results Firmly focused on execution of these priority projects as we expand our global industrial footprint to meet rising demand and evolving needs China Nearing the end of the design phase for regional EZ-fill® hub Anticip
Slide 8: Collaboration and Partnership Framework (DCS & DDS)
Collaboration and Partnership Framework (DCS & DDS) Second Quarter 2022 Financial Results Must anticipate market trends and help customers tackle their greatest challenges. This guides R&D, capital investments and partnerships. Our long-term strategy considers market trends and matching the needs of
Slide 9: European Natural Gas Pricing and Supply
Monitoring situation closely and it is something we must manage Energy costs have increased in the last six months. We are working directly with customers and adjusting prices accordingly Vast majority of our natural gas usage in Europe is in Italy for glass conversion Recent press reports indicate
Slide 10: 2021 Sustainability Report
Provides complete and transparent non-financial reporting to our stakeholders Most importantly, creates the foundation for setting future targets Considered the Company’s financial and economic results and highlights the ESG performance of the Group The Report is subject to limited assurance and was
Slide 11: Marco Dal Lago, Chief Financial Officer
Marco Dal Lago Chief Financial Officer
Slide 12: Second Quarter 2022 Financial Highlights
Second Quarter 2022 Financial Highlights Second Quarter 2022 Financial Results €204.0 €234.2 Revenue Y/Y revenue increase driven by growth in both segments. Covid represented ~9% of revenue in Q2 2022. Excluding favorable FX and Covid, Y/Y revenue grew ~17% Gross Profit Y/Y gross profit margin incre
Slide 13: Second Quarter 2022 Segment Financial Summary
Second Quarter 2022 Segment Financial Summary Second Quarter 2022 Financial Results BIOPHARMACEUTICAL AND DIAGNOSTIC SEGMENT (BDS) Despite decrease in Covid revenue, BDS revenue still grew 8% over last year (~3% on a constant currency basis) Y/Y revenue growth driven by a 46% increase in HVS to €70.
Slide 14: A Healthy Financial Position to Invest in Growth
A Healthy Financial Position to Invest in Growth Second Quarter 2022 Financial Results * Free Cash Flow, Capital Expenditures (CAPEX) and Net Cash are non-GAAP measures Please refer to slides 20-26 for a reconciliation of non-GAAP measures QUARTER ENDED June 30, 2022 €109.4M Net Cash* €77.5M Capital
Slide 15: Increasing 2022 Guidance
Increasing 2022 Guidance Second Quarter 2022 Financial Results *Adjusted DEPS and Adjusted EBITDA are non-GAAP measures. Please refer to slides 20-26 for a reconciliation of non-GAAP measures A decrease in revenue attributable to COVID. This is being offset by strong demand in our core business. FY2
Slide 16: Franco Moro, Chief Executive Officer & Chief Operating Officer
Franco Moro Chief Executive Officer & Chief Operating Officer
Slide 17: Summary: Operating Amid a Challenging but Favorable Environment
Summary: Operating Amid a Challenging but Favorable Environment Strong demand Growing end markets Multi-year secular drivers Satisfying customers’ needs by driving innovation and providing a rich set of end-to-end capabilities through the entire drug life cycle Executing four pillars of 2022 strateg
Slide 18: Notes to Non-GAAP Financial Measures
Notes to Non-GAAP Financial Measures: This presentation contains non-GAAP measures Second Quarter 2022 Financial Results Management monitors and evaluates our operating and financial performance using several non-GAAP financial measures, including Constant Currency Revenue, EBITDA, Adjusted EBITDA,
Slide 19: Reconciliation of Constant Currency
Reconciliation of Non-GAAP Measures Reconciliation of Constant Currency Second Quarter 2022 Financial Results Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) Six months ended June 30, 2022Biopharmaceutical and Diagnostic SolutionsEngineeringReported Revenue (IFRS GAAP)
Slide 20: Reconciliation of EBITDA
Reconciliation of Non-GAAP Measures Reconciliation EBITDA Second Quarter 2022 Financial Results Reconciliation of EBITDA (Unaudited) (Amounts in € millions)
Slide 21: Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Net Profit and EPS
Reconciliation of Non-GAAP Measures Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit and Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Second Quarter 2022 Financial Results (1) During the three months and six months ended June 30, 20
Slide 22: Reconciliation of Free Cash Flow
Reconciliation of Non-GAAP Measures Reconciliation of Free Cash Flow Second Quarter 2022 Financial Results Free Cash Flow (Amounts in € millions) For the three months ended June 30,For the six months ended June 30,2022202120222021Cash flow from operating activities42.254.147.460.0Interest paid1.01.2
Slide 23: Reconciliation of Net Cash
Reconciliation of Non-GAAP Measures Second Quarter 2022 Financial Results Net Cash (Amounts in € millions) As of June 30,As of December 31,20222021Non-current financial liabilities(175.4)(202.3)Current financial liabilities(60.9)(46.2)Other current financial assets30.927.2Cash and cash equivalents31
Slide 24: Reconciliation of Capital Expenditures
Reconciliation of Non-GAAP Measures Second Quarter 2022 Financial Results Capital Expenditures (Amounts in € millions) Reconciliation of Capital Expenditures (Amounts in € millions, except as indicated otherwise)For the three monthsended June 30,ChangeFor the six monthsended June 30,Change20222021€2
Slide 25: Reconciliation of Adjusted Guidance
Reconciliation of Non-GAAP Measures Reconciliation of Adjusted Guidance Second Quarter 2022 Financial Results Reconciliation of 2022 Guidance for Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS (Unaudited) (Amounts in € millions, except per share data)
Slide 26: Contacts
Contacts: Media Stevanato Group media@stevanatogroup.com Investor Relations Lisa Miles Lisa.miles@stevanatogroup.com